Seraxis’ manufacturing suite completes GMP quality system audit ahead of SR-02 IND filing and transplantation of pancreatic clusters to patients with Type 1 Diabetes
Seraxis Announces Publication of Preclinical Data for a Novel Islet Replacement Therapy and Clinical Candidate SR-02 for Insulin-Requiring Diabetes; Oral Presentation at IPITA
Seraxis to provide oral update on its pancreatic organoid candidate for functional cure of T1D at the 59th Annual Meeting of the EASD
Seraxis announces closing of second VC tranche and successful completion of preclinical studies of pancreatic organoids from Seraxis’ novel pancreas-derived stem cells
Late-Breaking Results of a Preclinical Efficacy Study presented at ENDO 2023 show Seraxis SRE Sustainably Reverses Type-1-Diabetes Hyperglycemia
Seraxis Presents Successful Results Using Synthetic Replacement Endocrine Clusters for Type 1 Diabetes at the 4th IPITA / HSCI / JDRF Summit
SERAXIS announces Appointment of Chief Medical Officer, Dr. Paul Strumph
SERAXIS Inc. publishes clinical trial considerations for a type 1 diabetes stem cell-derived therapy.
SERAXIS Inc. announces novel method and cell line that generate highly pure populations of insulin-producing cells capable of reversing diabetes in rodents.
Seraxis Inc. announces a commercialization grant award from the Maryland Stem Cell Research Fund (MSCRF)
Seraxis Inc. closed a Series B financing Round and enters into a collaboration with Medytox Inc.